Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 97 matching trials from the live ClinicalTrials.gov search.
Conditions
Smoldering Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Interventions
Health Coaching, Prolonged Overnight Fasting (POF), Mediterranean Diet, Supportive Materials
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Miami, Florida
Conditions
Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
darbepoetin alfa, epoetin alfa
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
darbepoetin alfa, ferrous sulfate, sodium ferric gluconate complex in sucrose, placebo
Biological · Dietary Supplement · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Conditions
Multiple Myeloma
Interventions
KW-2478, Bortezomib
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
9
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 6 more
Conditions
Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition
Interventions
filgrastim, cyclosporine, methylprednisolone, prednisone, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
10 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Coronavirus
Interventions
Questionnaire
Behavioral
Lead sponsor
HealthTree Foundation
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Lehi, Utah
Conditions
Multiple Myeloma, Waldenstrom's Macroglobulinemia, Smoldering Multiple Myeloma, Lymphoblastic Lymphoma
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Interventions
Relaxation Response Resiliency Program (3RP)
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Peripheral Neuropathy, Monoclonal Gammopathy of Undetermined Significance
Interventions
Daratumumab and hyaluronidase-fihj
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Conditions
Plasma Cell Dyscrasias, Monoclonal Gammopathy of Undetermined Significance, AL Amyloidosis, Multiple Myeloma
Interventions
tissue banking
Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2050
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Multiple Myeloma, Smoldering Myeloma, Waldenstrom's Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance, Amyloidosis
Interventions
biologic sample preservation procedure
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
207
States / cities
Little Rock, Arkansas • Berkeley, California • Burlingame, California + 141 more
Recruiting No phase listed Observational Accepts healthy volunteers

CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study

NCT06644625
Conditions
Multiple Myeloma, Multiple Myeloma Progression, Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), Plasma Cell Disorders
Interventions
Blood draw for the laboratory assessment
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
30 Years and older
Enrollment
1,665 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2035
U.S. locations
1
States / cities
Charlotte, North Carolina
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fentanyl citrate, pharmacological study
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Monoclonal Gammopathy of Undetermined Significance, Plasma Cell Myeloma
Interventions
5-Carbon C 13-labeled Glutamine, Biospecimen Collection, Uniformly-labeled [13C]glucose
Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fluorouracil, leucovorin calcium, topotecan hydrochloride
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Conditions
Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions
Bone Marrow Aspirate and Biopsy
Procedure
Lead sponsor
Michael Tomasson
Other
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Influenza, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Plasma Cell Disorders, MGUS
Interventions
Fluzone High Dose Vaccine, Standard of care/Placebo
Biological
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
St. John's wort
Dietary Supplement
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Conditions
Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Interventions
Multiple Myeloma M-Protein Analysis, Multiple Myeloma Knowledge Questionnaires
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
50 Years and older
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Waldenstrom Macroglobulinemia, Lymphocytosis, Lymphoma, Non-Hodgkin, B-Cell Chronic Lymphocytic Leukemia, Hematological Malignancies
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pyroxamide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
New York, New York
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
clarithromycin, prasterone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota